RT Conference Proceedings
T1 A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis
A1 Szabados, B. E.
A1 Rodriguez-Vida, A.
A1 Duran, I.
A1 Crabb, S. J.
A1 van-der-Heijden, M. S.
A1 Pous, A. Font
A1 Gravis, G.
A1 Herranz, U. Anido
A1 Protheroe, A.
A1 Ravaud, A.
A1 Maillet, D.
A1 Mendez, M. J.
A1 Suarez, C.
A1 Linch, M.
A1 Prendergast, A.
A1 Tyson, C.
A1 Mousa, K.
A1 Castellano, D.
A1 Powles, T. B.
K1 Cisplatin
K1 atezolizumab
K1 Urinary Bladder Neoplasms
K1 Muscles
AB Background. ABACUS is a phase II single-arm study that evaluated the safety and efficacy of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) awaiting radical cystectomy (RC).Methods. This single arm, phase II study investigated two cycles of atezolizumab (1200mg given every 3 weeks) prior to RC in MIBC(T2-4aN0M0) (NCT02662309). The study included patients who were ineligible or refused neoadjuvant cisplatin-based chemotherapy and had transitional cell histology. Pathological complete response (pCR) was the primary endpoint. Adverse events (AEs) and surgical complications were assessed using CTCAE v4.03 and the Clavien-Dindo classification.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-11-01
LK https://hdl.handle.net/10668/25477
UL https://hdl.handle.net/10668/25477
LA en
NO Szabados, B. E. Rodriguez-Vida, A. Duran, I., Crabb, S. J., van-der-Heijden, M. S., Pous, A. Font et al. A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Ann. oncol.2020; (31);S1319
DS RISalud
RD Apr 17, 2025